



ASX / MEDIA RELEASE 20TH December 2010

Compumedics to present to USA Investors Corporate Overview and Strategic Growth Imperatives at the 3rd Biotech Showcase™ and the 4th OneMed Annual Conferences

Major milestone advancing Compumedics global investor awareness and Compumedics value realisation

MELBOURNE, 20 December 2010: Compumedics Limited (ASX:CMP) today announced that Dr David Burton, the Company's Chairman and Chief Executive Officer, will present at two upcoming biotechnology conferences in the USA. The Biotech Showcase and the OneMed Forum both will take place in San Francisco, California, during the healthcare finance community's largest annual gathering in January 2011.

The investor presentations will follow a sequence of key Compumedics deals on the back of Compumedics' NEUVO® EEG long-term monitoring product roll-out and the growing recognition of Compumedics range of home-sleep-testing monitors (recently announced to the ASX).

Dr. Burton will present at the 3rd Annual Biotech Showcase, to be held at Parc 55 Wyndham, San Francisco. This presentation is scheduled for Monday, 10th January 2011 at 5.00 pm, San Francisco time.

Dr. Burton will present at the 4th Annual OneMedForum, to be held at the Sir Francis Drake Hotel, San Francisco. This presentation is scheduled for Wednesday 12th January 2011 at 10.45 am, San Francisco time.

About Compumedics Ltd: Compumedics is a global, leading designer and supplier of high-tech sleep, brain, and ultrasonic blood-flow monitoring systems for sleep, neurological and other associated healthcare problems. Each of these markets is multi-billion dollar in scope, at an early phase of evolution, and with high growth expectations. Compumedics is a profitable company, uniquely positioned for imminent growth in each of these markets.

Compumedics Limited was founded in **1987** by current Chairman/CEO Dr. David Burton and today is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In **1987** Compumedics established Asia Pacific's first fully computerized sleep laboratory. Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian marketplaces for its sleep, neurological, and Doppler blood-flow diagnostic monitoring devices. In **1995** the company was selected to supply equipment to the US Sleep Heart Health Study, the world's largest sleep study of its kind, with over 8,000 participants scheduled by 2008. With headquarters in Melbourne, Australia and offices in the United States, and Europe its products are distributed in over 50 countries. In **1998** Compumedics was awarded the overall Australian Exporter of the Year. In **2000** Compumedics was listed on the Australian Stock Exchange. In **2002**, Compumedics acquired US-based **Neuroscan** - the world's leading supplier of instruments for brain research. In the US - the world's largest medical device market - Neuroscan holds around 90% of the market for brain-research products. In **2003** Compumedics was awarded the Frost & Sullivan Award for Market Expansion Strategy. In **2004**, Compumedics acquired Germany-based **DWL Elektronische GmbH**, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields. In **2006**, Compumedics was awarded the Frost and Sullivan Technology Leadership award for its innovative Somté® recorder product. In **2007**, Compumedics and its Chairman were inducted into the Victorian Manufacturing Hall of Fame. In **2008** the DWL division received a top 100 German Innovation award. With 20,000 systems installed globally across the finest hospital, universities and clinics Compumedics sales have grown more than 4-fold from \$9 million (1999) to \$39 million (2008). In **2009** Compumedics was awarded a design award for its GRAEL® PSG/EEG premium laboratory-based product. In **2010** Compumedics was recognized by the Australian Innovation Government and Industry body as one of Australia's Top 100 Health Innovators through its' world leading devices for sleep diagnostics. **For further background please visit: www.compumedics.com**

<http://www.compumedics.com>

For further information please contact:

Compumedics CEO/Chairman: Dr. David Burton 61-3-8420-7300; dburton@compumedics.com.au

Bourse Communications: Mr. Rod North T: 03 9510 8309 M: 0408 670 706 E: rod@boursecommunications.com.au

Investors: CMP.ASX (ASX.COM)